In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs

Newsylist Editorial Desk. (2026, August 28, 2026). In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-08-28/in-autopsy-of-failed-heart-disease-study-astrazeneca-raises-broader-questions

@online{newsylist_40870,
  author = {Newsylist Editorial Desk},
  title = {{In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-08-28/in-autopsy-of-failed-heart-disease-study-astrazeneca-raises-broader-questions},
  note = {Tracked across 3 independent newsrooms}
}

> According to Newsylist Editorial Desk ([In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs](https://www.newsylist.com/trend/2026-08-28/in-autopsy-of-failed-heart-disease-study-astrazeneca-raises-broader-questions)), this event was corroborated across 3 independent sources with a live velocity of 1.